ACON

Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflows Advancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated in Q4 2026 Strengthened IP footprint with new AI patent and 64 total issued and pending patents worldwide Announced $2.5 million share repurchase program Strong balance sheet, no debt and cash runway into the second half of 2027, reinforcing long-term growth strategy BROOMFIELD, Colo., April 30, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today reported first quarter 2026 results highlighted by accelerating clinical adoption and strong execution across key strategic initiatives. Market Adoption Momentum Nociscan scan volumes increased 196% year-over-year (Q1 2026 vs. Q1 2025) 64% sequential scan volume growth (Q1 2026 vs. Q4 2025) Growth was driven by both new account activation and deeper utilization within existing sites, signaling increasing integration into clinical workflows. Repeat usage trends reinforce the value proposition for Nociscan and position Aclarion for sustained expansion. The opportunity for Nociscan remains significant. Each year, approximately 5.8 million lumbar MRIs1 (without contrast) are performed in the U.S. for low back pain, highlighting a large population where additional insights into the source of pain may be valuable. As adoption expands, Aclarion believes this represents a potential $2 billion market opportunity1 for technologies like Nociscan that can provide objective, data-driven evaluation of discogenic pain. Catalysts Driving Growth Nociscan has been reimbursed for several months by Vitality, AXA, and Aviva—three of the four largest private insurers in the U.K. This early payer adoption provides meaningful validation and a pathway for broader coverage expansion. Launch of a targeted direct-to-patient campaign in the U.K. Campaign includes a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic, one of the United Kingdom’s leading private hospitals. The video is available he...

Net loss: US$1.60m (loss widened by 29% from 2Q 2024). US$2.75 loss per share. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 36%. Earnings per share (EPS) also missed analyst estimates by 22%. Looking ahead, revenue is forecast to grow 95% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Performance of the American Healthcare Services industry. The company's shares are up 2.1% from a week ago. We don't want to rain on the parade too much, but we did also find 5 warning signs for Aclarion (4 don't sit too well with us!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.